Verified Nov 2026
Other
·
San Diego, California
·
Since 1979
Halozyme, Inc. is a biopharmaceutical company headquartered in San Diego, California, founded in 1979. It is publicly traded under the ticker HALO and employs between 200 and 500 people, with reported revenue of about $1.4 billion. The company serves the life sciences and healthcare industries, with its ENHANZE drug-delivery technology enabling subcutaneous administration of biologic therapies. In January 2026, it announced a global collaboration and license agreement with Takeda to develop and commercialize vedolizumab using that technology.
Halozyme, Inc. at a glance
Revenue
1.4B
Employees
200-500
Founded
1979
Headquarters
San Diego, California
Ownership
Publicly traded (NASDAQ: HALO)
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
Halozyme, Inc. is a biopharmaceutical company headquartered in San Diego, California, founded in 1979. It is publicly traded under the ticker HALO and employs between 200 and 500 people, with reported revenue of about $1.4 billion. The company serves the life sciences and healthcare industries, with its ENHANZE drug-delivery technology enabling subcutaneous administration of biologic therapies. In January 2026, it announced a global collaboration and license agreement with Takeda to develop and commercialize vedolizumab using that technology.
At a glance
Attribute | Detail |
|---|---|
Founded | 1979 |
Headquarters | San Diego, California |
Employees | 200-500 |
Revenue | 1.4B |
Ownership | Publicly traded (NASDAQ: HALO) |
What Halozyme, Inc. makes
The company's flagship ENHANZE technology is a patented enzyme platform for subcutaneous drug delivery, and its listed industries include medical and automotive, though no certifications are recorded in the source data.
Latest developments
2026-11-05 — Halozyme Therapeutics, Inc. - HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE (halozyme.com)
2026-10-06 — Halozyme Therapeutics, Inc. - Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology (halozyme.com)
2026-04-07 — Vertex taps Halozyme in $15M upfront biologics drug delivery deal (fiercepharma.com)
2026-01-28 — Halozyme catches M&A wave to snap up Surf Bio (fiercepharma.com)
2026-01-08 — Halozyme Therapeutics, Inc. - Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® (halozyme.com)
2025-11-18 — Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery (prnewswire.com)
Facilities
Halozyme, Inc. is headquartered in San Diego, California. Public sources also reference these locations:
Boston, MA — halozyme.com
Company details
Halozyme is a publicly listed company whose reported revenue band is about $1.4 billion, and its record lists industries including medical, electric vehicles, and industrial equipment. Halozyme, Inc. was founded in 1979, has an estimated 200-500 employees, and is headquartered in San Diego, California.
Frequently asked questions
What does Halozyme, Inc. do?
Halozyme, Inc. is a biopharmaceutical company headquartered in San Diego, California, founded in 1979. It is publicly traded under the ticker HALO and employs between 200 and 500 people, with reported revenue of about $1.4 billion. The company serves the life sciences and healthcare industries, with its ENHANZE drug-delivery technology enabling subcutaneous administration of biologic therapies. In January 2026, it announced a global collaboration and license agreement with Takeda to develop and commercialize vedolizumab using that technology.
Where is Halozyme, Inc. headquartered?
Halozyme, Inc. is headquartered in San Diego, California (12390 El Camino Real, San Diego, California, 92130-2081).
When was Halozyme, Inc. founded?
Halozyme, Inc. was founded in 1979.
How big is Halozyme, Inc.?
Halozyme, Inc. has an estimated 200-500 employees, with revenue in the 1.4B range.
Is Halozyme, Inc. publicly traded?
Publicly traded (NASDAQ: HALO). Public financial figures are drawn from its filings.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.